Company intelligence / Profile preview

CureApp

Ownership: Private
Employees: ~100
Development stage: Other

Overview

CureApp has achieved Japan’s first regulatory approval and insurance reimbursement for a prescription digital therapeutic app targeting nicotine addiction. Its hypertension app is also approved and reimbursed in Japan, with published Phase III data showing significant blood pressure reduction. Other programs are in clinical or pre-commercial stages.

Therapeutic areas: PsychiatryGastroenterologyOncologyCardiovascular
Modalities: DeviceNon-pharmacological therapy
Industry: Digital Health Medical Devices

Partnerships

Teijin PharmaSawai Group Holdings Co.University of Tokyo HospitalNational Hospital Organization Kurihama Medical and Addiction CenterDaiichi SankyoYumino Medical Corporation

Beyond the preview

Go deeper on CureApp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CureApp.

Explore the full profile